Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
Michael Rossi, R.Ph. was appointed President of Jubilant DraxImage in October 2016. Michael joined Jubilant DraxImage in April 2014, serving as Vice Presidents of Sales, Marketing and Business Operation. He is a proven leader with more than 20 years of experience in the Pharmaceutical Industry focusing on Nuclear Medicine, Imaging, and Medical Devices. Michael held leadership roles with GE Healthcare and Mallinckrodt. He has successfully lead large commercial teams in both North America and abroad. Michael holds a Bachelor of Science Degree in Pharmacy from University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania. Mike was a Board Certified Nuclear Pharmacist for 15 years and is currently a registered pharmacist in the state of Pennsylvania.
Dr. LaFrance, MD, ME, FACP, FACNP, joined Jubilant DraxImage in 2012 as Chief Medical Officer [CMO] and SVP, Medical & Regulatory Affairs. His broad experience spans over thirty-five years in the practice of medicine, pharmaceutical and healthcare industry, drug research & development and commercialization work with large pharmaceutical and specialty pharmaceutical, molecular imaging and therapeutic companies. Dr. LaFrance has had numerous submitted and approved NDA’s and many additional, successful phase 0-IV programs to his credit. Dr. LaFrance’s experience includes not only North America, but also Europe, Japan, Latin America, Asia and ROW. Important aspects of his responsibilities over the years included identifying, establishing and developing collaborations between industry, government and academia while supporting business development, marketing, and in-licensing objectives through a core of clinical, medical & regulatory affairs expertise. Prior to industry, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in Internal Medicine and Nuclear Medicine, maintains active Medical Licensure in the United States along with active, professional society membership.
Douglas Gentilcore was appointed Vice-President, Global Sales in July 2017 after leading the transformation of the sales organization, as the Director of U.S. Sales. In that role, he improved the company’s contractual procedures by implementing new and important quality standards, which ensures the delivery and increased quality of Jubilant DraxImage products to patients across the United States. He joined Jubilant DraxImage in May 2014, bringing with him over 13 years of successful and innovative sales experience within the medical and healthcare industry—including Pfizer and GE Healthcare. Doug holds a Bachelor of Arts degree in Business-Economics from Randolph-Macon College in Ashland, Virginia.
James Kaufman was appointed Vice-President, Marketing in August 2017. Jim joined the company in November 2016 bringing with him over 20 years of medical imaging experience with a strong proficiency in nuclear medicine and business development. Since joining, he has been instrumental in the successful launch of the RUBY-FILL® Rubidium (Rb-82) Generator and Ruby Rubidium Elution System. Prior to joining Jubilant DraxImage, he served as a Global Product Leader, Life Sciences-Core Imaging at GE Healthcare, specializing in the Cardiology product segment, as well as Neurology, Oncology and overall general nuclear imaging segments. Jim holds a Bachelor of Science in Business Administration and Marketing from Ashland University. He received his Nuclear Medicine Technology training at The Ohio State University.
Dr. Toni Rinow was appointed General Manager of Jubilant DraxImage in July 2018. Her professional career includes leadership roles in both public and private pharmaceutical and healthcare organizations, where she spearheaded acquisitions across Canada, Latin America, and India and supported the transition of two biotechnology companies to an initial public offering at the Toronto Stock Exchange. In addition to her Masters of Business Administration degree (MBA) from McGill University, she holds a doctorate in physical chemistry from the Université de Montréal (Ph.D), and a chemical engineering degree from the European Higher Institute of Chemistry in Strasbourg, France. Dr. Rinow believes in giving back to the community and sits on the Board of Directors in several non-for profit organizations.
Ms. Arpita Chatterjee was appointed the Vice-President, Finance in April 2016. With over 22 years’ experience in finance and accounting, her main areas of expertise are financial reporting, management of global budgets, interpretation of financial data and staff management. More recently, she worked as Global Director, Finance and Administration for MIP Inc – Montreal. Arpita is responsible for the JHS and JDI finance departments. Arpita holds a Bachelor of Commerce and is a member of the CPA.
Dr. Riddoch, B.Sc., Ph.D. has headed the Research and Development group since November 2014 and is responsible for overseeing Jubilant DraxImage’s development pipeline as well as the radiation safety program. Prior to this Dr. Riddoch served in several different positions: Director of Manufacturing Operations (2012-2014), Senior Manager of Research and Development (2011 – 2012) and Senior Scientist (2001 – 2011). Over his career he has been responsible for the development, validation and trouble shooting of many of the products which make up the company’s current Product Portfolio. Dr. Riddoch is an experienced radiochemist, whose research has focused on technetium chelation chemistry and radiohalogen chemistry. He holds an honours B.Sc. and a Ph.D. in Chemistry from McMaster University.
Ms. Tara Pradhan joined Jubilant with over 16 years’ experience in the pharmaceutical industry, including 13 years in quality control, validation and employee management for companies such as Wyeth / Pfizer and TetraGenx. More recently, she worked as Manager, Quality and Validation for Church & Dwight Canada. Tara is responsible for the Quality Control and Quality Assurance departments. Tara holds a Bachelor of Science with a specialization in Biochemistry from Concordia University.